Basics Editas Medicine, Inc. Editas Medicine Inc is a genome editing company which is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. IPO Date: February 3, 2016 Sector: Healthcare Industry: Biotech Market Cap: $248.18M Activated in VL: True Average Daily Range Avg Daily Range: $0.71 | 3.38% Avg Daily Range (30 D): $0.12 | 4.49% Avg Daily Range (90 D): $0.10 | 4.62% Institutional Daily Volume Avg Daily Volume: 1.27M Avg Daily Volume (30 D): 1.69M Avg Daily Volume (90 D): 2.09M Trade Size Avg Trade Size (Sh.): 109 Avg Trade Size (Sh.) (30 D): 177 Avg Trade Size (Sh.) (90 D): 223 Institutional Trades Total Inst.Trades: 3,807 Avg Inst. Trade: $2.01M Avg Inst. Trade (30 D): $1.99M Avg Inst. Trade (90 D): $1.17M Avg Inst. Trade Volume: .1M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $2.78M Avg Closing Trade (30 D): $2.44M Avg Closing Trade (90 D): $1.4M Avg Closing Volume: 159.3K     News Sep 2, 2025 @ 10:00 AM Gene Editing Market to Surpass USD 15.46 Billion b... Source: Sns Insider Jun 27, 2025 @ 12:15 PM 2 Beaten-Down Stocks to Avoid Source: Prosper Junior Bakiny Jun 17, 2025 @ 2:07 PM Editas Medicine Is Great. Here's Why You Shouldn't... Source: Dan Victor Jun 12, 2025 @ 6:01 AM Editas Medicine Reports Proprietary Targeted Lipid... Source: Editas Medicine Mar 6, 2025 @ 6:00 PM Global Genome Editing Market to Grow Rapidly at a ... Source: Delveinsight Financials   TTM Q2 2025 Q1 2025 Basic EPS $-2.85 $-.63 $-.92 Diluted EPS $-2.85 $-.63 $-.92 Revenue $ 38.9M $ 3.58M $ 4.66M Gross Profit $ $ $ Net Income / Loss $ -236.86M $ -53.24M $ -76.09M Operating Income / Loss $ -239.97M $ -51.54M $ -76.16M Cost of Revenue $ $ $ Net Cash Flow $ 74.1M $ -.15M $ 7.15M PE Ratio